Compare CDRO & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRO | BBOT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.2M | 442.6M |
| IPO Year | 2021 | 2024 |
| Metric | CDRO | BBOT |
|---|---|---|
| Price | $8.30 | $1.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $12.00 | ★ $20.91 |
| AVG Volume (30 Days) | 24.8K | ★ 655.9K |
| Earning Date | 02-28-2023 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $305.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.19 | $1.92 |
| 52 Week High | $10.26 | $14.87 |
| Indicator | CDRO | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 29.53 |
| Support Level | $7.74 | N/A |
| Resistance Level | $9.61 | $2.95 |
| Average True Range (ATR) | 0.46 | 0.25 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 27.18 | 2.30 |
Codere Online Luxembourg SA is an international online casino gaming and online sports betting group focused on providing its customers with a safe and enjoyable online gaming experience. It currently operates in Spain, Mexico, Colombia, and Other countries, where it offers its users the ability to play online casino games and bet on sports events. Online casino offerings include the full portfolio of games typically available in land-based casinos, gaming halls, and gambling establishments, such as slot machines, table games, and bingo. Online sports betting involves a user placing a wager on an event at some fixed odds determined by Codere Online. The company derives maximum revenue from Mexico.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.